(Reuters) -Merck said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics’ experimental flu drug.
The drugmaker struck a deal worth nearly $9.2 billion last week to acquire Cidara to gain access to the long-acting antiviral drug, CD388, currently in late-stage trial.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Brought to you by www.srnnews.com